Jeffrey Hung
Stock Analyst at Morgan Stanley
(2.34)
# 2,526
Out of 4,858 analysts
206
Total ratings
41.88%
Success rate
-1.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Equal-Weight | $20 → $24 | $22.30 | +7.62% | 25 | May 20, 2025 | |
| CTNM Contineum Therapeutics | Maintains: Overweight | $25 → $20 | $4.58 | +336.68% | 3 | May 19, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $55 → $52 | $26.18 | +98.62% | 3 | May 19, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $64 → $65 | $37.51 | +73.29% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $183 → $166 | $110.50 | +50.23% | 6 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Equal-Weight | $15 → $17 | $8.76 | +94.06% | 5 | May 6, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $37 → $34 | $3.21 | +959.19% | 3 | Mar 11, 2025 | |
| RYTM Rhythm Pharmaceuticals | Assumes: Overweight | $72 | $64.84 | +11.04% | 11 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Assumes: Overweight | $67 → $70 | $50.79 | +37.82% | 11 | Mar 7, 2025 | |
| NBIX Neurocrine Biosciences | Assumes: Overweight | $185 → $150 | $124.17 | +20.80% | 26 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $4 | $1.52 | +163.16% | 3 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $50.86 | +67.13% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $38 → $35 | $8.98 | +289.76% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $12.47 | +116.52% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Underweight | $5 | $4.45 | +12.36% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $70 → $67 | $33.11 | +102.36% | 13 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $17 → $12 | $6.15 | +95.28% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $7.47 | +368.54% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $32.36 | +116.32% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $1.10 | +265.30% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $7.86 | -49.11% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $0.87 | +360.30% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $2.12 | +560.38% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.53 | +41.64% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $1.21 | +147.93% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.44 | +872.22% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.80 | +455.56% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $41.43 | -46.90% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $15.69 | +846.46% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $1.83 | +3,178.69% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.38 | +77.51% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.62 | +8,676.92% | 6 | May 8, 2020 |
ACADIA Pharmaceuticals
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.30
Upside: +7.62%
Contineum Therapeutics
May 19, 2025
Maintains: Overweight
Price Target: $25 → $20
Current: $4.58
Upside: +336.68%
CG Oncology
May 19, 2025
Maintains: Overweight
Price Target: $55 → $52
Current: $26.18
Upside: +98.62%
Ultragenyx Pharmaceutical
May 9, 2025
Maintains: Overweight
Price Target: $64 → $65
Current: $37.51
Upside: +73.29%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Overweight
Price Target: $183 → $166
Current: $110.50
Upside: +50.23%
Bicycle Therapeutics
May 6, 2025
Maintains: Equal-Weight
Price Target: $15 → $17
Current: $8.76
Upside: +94.06%
enGene Holdings
Mar 11, 2025
Maintains: Overweight
Price Target: $37 → $34
Current: $3.21
Upside: +959.19%
Rhythm Pharmaceuticals
Mar 7, 2025
Assumes: Overweight
Price Target: $72
Current: $64.84
Upside: +11.04%
PTC Therapeutics
Mar 7, 2025
Assumes: Overweight
Price Target: $67 → $70
Current: $50.79
Upside: +37.82%
Neurocrine Biosciences
Mar 7, 2025
Assumes: Overweight
Price Target: $185 → $150
Current: $124.17
Upside: +20.80%
Mar 7, 2025
Assumes: Overweight
Price Target: $4
Current: $1.52
Upside: +163.16%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $50.86
Upside: +67.13%
Mar 7, 2025
Assumes: Overweight
Price Target: $38 → $35
Current: $8.98
Upside: +289.76%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $12.47
Upside: +116.52%
Mar 7, 2025
Assumes: Underweight
Price Target: $5
Current: $4.45
Upside: +12.36%
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $33.11
Upside: +102.36%
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $6.15
Upside: +95.28%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $7.47
Upside: +368.54%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $32.36
Upside: +116.32%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $1.10
Upside: +265.30%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $7.86
Upside: -49.11%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $0.87
Upside: +360.30%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $2.12
Upside: +560.38%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.53
Upside: +41.64%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.21
Upside: +147.93%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.44
Upside: +872.22%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.80
Upside: +455.56%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $41.43
Upside: -46.90%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $15.69
Upside: +846.46%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $1.83
Upside: +3,178.69%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.38
Upside: +77.51%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.62
Upside: +8,676.92%